The Utilization of Topical Insulin for Ocular Surface Diseases: A Narrative Review.

corneal epithelial defect corneal wound healing diabetic keratopathy dry eye disease insulin-like growth factor limbal epithelial stem cell neurotrophic keratopathy persistent epithelial defect substance p topical insulin

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2024
Historique:
accepted: 09 06 2024
medline: 11 7 2024
pubmed: 11 7 2024
entrez: 11 7 2024
Statut: epublish

Résumé

Various etiologies, including diabetic keratopathy (DK), dry eye disease (DED), and neurotrophic keratopathy (NK), can disrupt corneal homeostasis, exacerbating corneal epithelial defects. Topical insulin has emerged as a promising therapy for promoting corneal wound healing and addressing underlying pathologies. This review systematically evaluates the efficacy of topical insulin across different corneal disorders. A literature review was conducted across the PubMed, Google Scholar, and Scopus research databases. The search resulted in a total of 19 articles, consisting of clinical trials, retrospective studies, and case reports. In DK, topical insulin accelerates corneal wound healing post-vitreoretinal surgery with lower concentrations showing higher outcomes when compared to conventional therapy, possibly due to improved epithelial stem cell migration. In comparison, the dry-eye disease results are inconclusive regarding patient-reported outcomes and corneal staining. For NK, topical insulin accelerates corneal wound healing and restores corneal nerve sensation. Other persistent epithelial defect (PED) etiologies that have been treated with topical insulin are infection, immune-mediated, mechanical and chemical trauma, and chronic ocular surface alterations. Although individual mechanisms for the benefits of topical insulin for each of these etiologies have not been studied, the literature demonstrates that topical insulin is efficacious for PEDs regardless of etiology. Future clinical trials need to be conducted to further evaluate optimal dosing, duration, and use of topical insulin for the restoration of the corneal surface.

Identifiants

pubmed: 38989397
doi: 10.7759/cureus.62065
pmc: PMC11235153
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e62065

Informations de copyright

Copyright © 2024, Moin et al.

Déclaration de conflit d'intérêts

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Kayvon A Moin (KA)

Hoopes Vision Research Center, Hoopes Vision, Draper, USA.

Srujay Pandiri (S)

Ophthalmology, University of Missouri Kansas City School of Medicine, Kansas City, USA.

Garrett N Manion (GN)

Ophthalmology, Creighton University School of Medicine, Omaha, USA.

Alex H Brown (AH)

Ophthalmology, University of Arizona College of Medicine - Phoenix, Phoenix, USA.

Majid Moshirfar (M)

Eye Banking and Corneal Transplantation, Utah Lions Eye Bank, Murray, USA.
Corneal and Refractive Surgery, Hoopes Vision Research Center, Draper, USA.

Phillip C Hoopes (PC)

Hoopes Vision Research Center, Hoopes Vision, Draper, USA.

Classifications MeSH